If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Reyvow ® (lasmiditan) tablets CV
50 mg, 100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Reyvow® (lasmiditan) be used concomitantly with oral CGRP receptor antagonists?
The concomitant use of Reyvow (lasmiditan) with oral CGRP antagonists being taken for acute or preventive treatment of migraine has not been studied
The Use of Lasmiditan With Oral Calcitonin Gene-Related Peptide Receptor Antagonists Has Not Been Studied
The use of lasmiditan concomitantly with oral calcitonin gene-related peptide (CGRP) receptor antagonists for acute or preventive migraine treatment has not been studied, and the safety and efficacy of their concomitant use is unknown.
Oral CGRP receptor antagonists approved for use in the acute or preventive treatment of migraine in adults are listed in .
Oral CGRP Receptor Antagonist |
Acute Treatment of Migraine |
Migraine Prevention |
Atogepant |
No |
Yes |
Rimegepant |
Yes |
Yes |
Ubrogepant |
Yes |
No |
Abbreviation: CGRP = calcitonin gene-related peptide.
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Deeks ED. Atogepant: first approval. Drugs. 2022;82(1):65-70. https://doi.org/10.1007/s40265-021-01644-5
2Scott LJ. Rimegepant: first approval. Drugs. 2020;80(7):741-746. http://dx.doi.org/10.1007/s40265-020-01301-3
3Scott LJ. Ubrogepant: first approval. Drugs. 2020;80(3):323-328. http://dx.doi.org/10.1007/s40265-020-01264-5
4Nurtec [package insert]. New Haven, CT: Biohaven; 2021.
Date of Last Review: May 23, 2022